Enanta Pharmaceuticals Ownership | Who Owns Enanta Pharmaceuticals?


OverviewForecastRevenueFinancialsChart

Enanta Pharmaceuticals Ownership Summary


Enanta Pharmaceuticals is owned by 125.09% institutional investors, 4.68% insiders. Janus henderson group is the largest institutional shareholder, holding 17.70% of ENTA shares. Vanguard US Total Market Shares ETF is the top mutual fund, with 2.95% of its assets in Enanta Pharmaceuticals shares.

ENTA Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockEnanta Pharmaceuticals125.09%4.68%-29.78%
SectorHealthcare Stocks 35.58%11.87%52.55%
IndustryBiotech Stocks 35.75%11.83%52.41%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Janus henderson group3.78M17.70%$47.72M
Blackrock funding, inc. /de3.10M14.52%$39.20M
Farallon capital management2.87M13.43%$36.27M
Krensavage asset management2.87M13.41%$36.20M
Vanguard group2.30M10.77%$36.30M
Deep track capital, lp1.96M9.15%$24.72M
Blackrock1.85M8.72%$23.96M
Millennium management882.10K4.13%$11.14M
Acadian asset management880.02K4.12%$11.10M
Commodore capital lp800.00K3.75%$9.58M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Krensavage asset management2.87M14.16%$36.20M
Commodore capital lp800.00K0.47%$9.58M
Deep track capital, lp1.96M0.40%$24.72M
Pharvision advisers35.85K0.24%$429.08K
Opaleye management125.00K0.21%$1.58M
Farallon capital management2.87M0.21%$36.27M
Stempoint capital lp75.19K0.18%$900.07K
Hillsdale investment management435.51K0.15%$5.50M
Diadema partners lp64.95K0.14%$820.34K
Persistent asset partners16.52K0.08%$208.71K

Top Buyers

HolderShares% AssetsChange
Commodore capital lp800.00K0.47%800.00K
Vanguard group2.30M0.00%362.96K
Millennium management882.10K0.00%211.67K
Vanguard fiduciary trust175.86K0.00%175.86K
Citadel advisors262.53K0.00%169.38K

Top Sellers

HolderShares% AssetsChange
Ra capital management---1.04M
Armistice capital---1.00M
Soleus capital management---785.55K
Point72 asset management---438.94K
Caligan partners lp---184.83K

New Positions

HolderShares% AssetsChangeValue
Commodore capital lp800.00K0.47%800.00K$9.58M
Vanguard fiduciary trust175.86K0.00%175.86K$2.22M
Stempoint capital lp75.19K0.18%75.19K$900.07K
Cubist systematic strategies49.98K0.00%49.98K$598.30K
Norges bank40.70K-40.70K$234.03K

Sold Out

HolderChange
Sbi securities-1.00
Nelson, van denburg & campbell wealth management group-4.00
Innealta capital-16.00
Advisor group-18.00
Voisard asset management group-28.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Mar 31, 2026129-1.53%26,744,9721.35%1251.48%70-14.63%3223.08%
Dec 31, 202553-57.94%8,402,898-55.75%390.50%30-50.82%11-72.50%
Sep 30, 202547-53.00%5,407,827-68.64%250.39%20-55.56%17-55.26%
Jun 30, 2025104-5.45%18,326,590-1.61%851.12%47-16.07%4110.81%
Mar 31, 20255-95.33%2,149,611-88.86%100.12%2-96.61%1-96.55%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Vanguard US Total Market Shares ETF629.60K2.95%-
Vanguard Total Stock Mkt Idx Inv852.43K2.93%-
iShares Russell 2000 ETF650.06K2.24%5.50K
BlackRock Health Sciences Opps Inv A492.00K1.69%-
Columbia Small Cap Value I A271.73K1.28%3.30K
Hillsdale US Small Cap Eq Fund Srs A U$352.70K1.22%352.70K
Vanguard Institutional Extnd Mkt Idx Tr301.21K1.04%2.12K
Vanguard Strategic Small-Cap Equity Inv280.93K0.97%-36.31K
Columbia Small Cap Value I200.68K0.95%200.68K
Fidelity Small Cap Index265.86K0.92%1.85K

Recent Insider Transactions


DateNameRoleActivityValue
Dec 05, 2025Capps Kathleen S. See RemarksSell$4.60K
Dec 05, 2025Trout Harry R. III See RemarksSell$7.71K
Dec 05, 2025Rottinghaus Scott T. Chief Medical OfficerSell$11.36K
Dec 05, 2025Luu Brendan Chief Business OfficerSell$19.84K
Dec 05, 2025Kieffer Tara Lynn Chief Product Strategy OfficerSell$29.97K

Insider Transactions Trends


DateBuySell
2026 Q1--
2025 Q4-9
2025 Q3--
2025 Q11-
2024 Q4-6

ENTA Ownership FAQ


Who Owns Enanta Pharmaceuticals?

Enanta Pharmaceuticals shareholders are primarily institutional investors at 125.09%, followed by 4.68% insiders and -29.77% retail investors. The average institutional ownership in Enanta Pharmaceuticals's industry, Biotech Stocks , is 35.75%, which Enanta Pharmaceuticals exceeds.

Who owns the most shares of Enanta Pharmaceuticals?

Enanta Pharmaceuticals’s largest shareholders are Janus henderson group (3.78M shares, 17.70%), Blackrock funding, inc. /de (3.1M shares, 14.52%), and Farallon capital management (2.87M shares, 13.43%). Together, they hold 45.65% of Enanta Pharmaceuticals’s total shares outstanding.

Does Blackrock own Enanta Pharmaceuticals?

Yes, BlackRock owns 8.72% of Enanta Pharmaceuticals, totaling 1.85M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 23.96M$. In the last quarter, BlackRock increased its holdings by 8.46K shares, a 0.46% change.

Who is Enanta Pharmaceuticals’s biggest shareholder by percentage of total assets invested?

Krensavage asset management is Enanta Pharmaceuticals’s biggest shareholder by percentage of total assets invested, with 14.16% of its assets in 2.87M Enanta Pharmaceuticals shares, valued at 36.2M$.

Who is the top mutual fund holder of Enanta Pharmaceuticals shares?

Vanguard US Total Market Shares ETF is the top mutual fund holder of Enanta Pharmaceuticals shares, with 2.95% of its total shares outstanding invested in 629.6K Enanta Pharmaceuticals shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools